The Brigham and Women's PGY2 Infectious Diseases Pharmacy Residency is recruiting for the 2026-27 year! Scan the second QR code below to schedule an on-demand meeting with program leadership and current residents
Wooo last OTILT, congrats!
Correct! Since AUCs >~650 have been associated with toxicity
We did include all MIC comers, but did not collect that data! We today still have no problem targeting an AUC of 400-600 for CoNS even with an MIC of 2, although not based on any great published data
🟢 Gepotidacin (Blujepa) approved March 25, 2025 www.accessdata.fda.gov/drugsatfda_d...
🟣 Sulopenem-probenecid (Orlynvah) approved October 2024 www.accessdata.fda.gov/drugsatfda_d...
🔵 Pivmecillinam (Pivya) approved April 2024 www.accessdata.fda.gov/drugsatfda_d...
Three new UTI antibiotics active vs. ESBL organisms have been approved by the FDA in the past year alone! Which will make it to market first: pivmecillinam, sulopenem-probenecid, or gepotidacin? #IDsky
The aztreonam-avibactam (Emblaveo) FDA approval Friday flew wayyyy under the radar without the normal FDA alerts or AMDAC review. But AbbVie has the press release (news.abbvie.com/2025-02-07-U...) and the FDA package insert is now available! www.accessdata.fda.gov/drugsatfda_d...
Yes, that’s exactly what we did! Should’ve put that in the methods
🆕💫 Narrative Review @cmicomms.bsky.social
@jeffpears0n.bsky.social
Tetracyclines, the Old and the New
🔹Tetracycline 1953
✨Doxycycline 1967
🔹Minocycline 1971
🔹Tigecycline 2005
🔹Eravacycline 2018
🔹Omadacycline 2018
#IDsky #EMIMCC
www.sciencedirect.com/science/arti...
Great to see the CACTUS study in print! authors.elsevier.com/c/1kHGc5E-Uo... Ceftaz-avi vs. Ceftol-tazo for MDR Pseudomonas. Tremendous effort by all involved, and thanks to a great leadership team. The PRECEDENT network is cooking up much more, check it out at www.precedentnetwork.com! #IDsky
I'm excited to join the #IDSky 🦋 community! What better way to start than with our study that flew under the radar last month integrating vancomycin AUC monitoring in OPAT, which saw HUGE drops in AKI rates (23% to 6% overall). Safe to say AUC is here to stay! academic.oup.com/ofid/article...
Thank you @IDSAInfo for this honor! I'm humbled to become a fellow of IDSA, especially being just 1 of 8 PharmDs recognized with #FIDSA this year. I can't wait to see everyone in LA in October at @IDWeekmtg! #WeAreID
Concomitant carbapenem & valproate use is THE most relevant drug interaction I teach residents & students about. In our review, seizures occured in 46% of encounters😱. Avoid this combination at all costs in patients using valproate for seizure control!
Alright #IDTwitter, what would you recommend in the situation below? Source control unattainable, infected graft so hoping for short-term acute treatment and long-term suppression. NDM positive Providencia rettgeri
Our new study evaluating gentamicin dosing strategies for endocarditis was published in @jac_amr! We saw HUGE rates of nephrotoxicity (~50%) in the divided dosing group. Next research question from our MGB group - time to ditch gent altogether?
Catching up on podcasts today, I had the best random back-to-back listening experience! Looking at the pip-tazo breakpoints from two different angles, great discussion in both from @SIDPharm and @ASMicrobiology & #IDTwitter
The tixagevimab-cilgavimab (Evusheld) EUA was revoked today by the FDA, marking the end of these #COVID Mab posts from me for the foreseeable future. #IDtwitter
ASPE/HHS published a breakdown of oral #COVID19 treatment utilization by state last week - Paxlovid vs. molnupiravir. As I expected, Massachusetts is on the far end of the spectrum favoring Paxlovid... #IDTwitter 1/2
The @US_FDA officially withdrew bebtelovimab's EUA this week as variant resistance has surpassed 65%, following in the steps of many #COVID Mabs before it. The only Mab left standing (barely) is Evusheld (79% resistant, but no alternatives) #IDTwitter
I also have joined med Mastodon and will likely be moving over to that platform gradually in the coming weeks, come along for the ride! #medmastodon #IDmastodon #IDTwitter
I missed last Friday's Tweet, so I added some extra insight in this post. Updated Mab variant table, with expected susceptibility against circulating variants in the second image (per ). We shut down bebtelovimab last week at BWH #IDTwitter #COVID19
While not much has changed on my Mab table since the last post, a whole lot has changed with the current #COVID variants. We're now looking at ~27% resistance to bebtelovimab and ~50% resistance to Evusheld. Stay tuned for updates from @NIHCOVIDTxGuide
This may need to be a weekly Tweet based on how quickly the #COVID19 Omicron variants are changing. Below is the updated COVID Mabs table, and just as importantly the variant situation right now in the US. Note the variants quickly rising to the top of the list... #IDTwitter
Omicron continues its never-ending variant kick! BA.4.6 & BA.2.75 are added below. This will be my last variant table that is all-inconclusive. In order to make more readable going forward it will just be with active(ish) variants and #COVID Mabs #IDTwitter
Our @BrighamPharmacy team has been on a vancomycin publication kick recently! Out today in @OFIDJournal, we report on our vanc accumulation rates in patients with obesity. Hint: it happens A LOT. Where's the #saynotovanco crowd at?! @PharmerMeg 😂
Just in time for the holiday weekend, the FDA authorized re-dosing of Evusheld every 6 months! They also snuck in neutralizing data for BA.4/5, so time for another table update! AstraZeneca says 33-65-fold reduction is OK, what say you? #COVID #IDTwitter
The bebtelovimab fact sheet was updated last week with info on BA.2.12.1, BA.4, and BA.5 (), which means it's time for an update to the #COVID variant table! #IDTwitter
This flew under the radar (even for me as an author!), but the @BrighamWomens team recently had an excellent (succinct) sepsis review paper published - we discuss time to abx in sepsis v. septic shock, prolonged vs. push 1st dose, order of admin, and more!
